VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

NCT ID: NCT04166383

Last Updated: 2023-11-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-09
• Study Completion Date: 2022-12-31

Brief Summary

Background:

Gastrointestinal cancer is one of the most common cancers worldwide. Researchers think an unmet need exists to understand and improve treatment options. They want to see if a combination of drugs can help people with metastatic colorectal cancer.

Objective:

To see if using a combination of Vascular Biogenics (VB)-111 and nivolumab is safe and will cause colorectal tumors to shrink.

Eligibility:

People ages 18 and older with microsatellite stable colorectal cancer that has spread to the liver

Design:

Participants must consent to sample collection protocol 11C0112.

Participants will be screened with:

Blood tests

Scans

Tumor samples. If these are not available, participants will have a biopsy.

Before they start treatment and with every treatment cycle, participants will have:

Physical exams

Blood tests

Heart tests

Before they start treatment and every 4 cycles, participants will have computed tomography (CT) or magnetic resonance imaging (MRI) scans. For these, they will lie in a machine that takes pictures of the body. For the MRI, a soft padding or coil will be placed around their head.

Participants will have biopsies before they start therapy. They will have them again after 2 6 weeks on study.

On day 1 of 14-day cycles, participants will get one or both study drugs by vein.

After they finish treatment, participants will have monthly visits for 3 months. They will have a physical exam and blood tests.

If participants stop treatment for reasons other than their disease getting worse, they will have scans about every 8 weeks. This will continue until their disease gets worse.

Participants will be contacted by phone or email every 6 months. This will continue for life.

...

Detailed Description

Background:

• Immune based approaches in gastrointestinal (GI) cancers have unfortunately- with the notable exception of immune checkpoint inhibition in microsatellite instable (MSI-H) disease and gastric cancer-been largely unsuccessful. The reasons for this are unclear but no doubt relate to the fact that in advanced disease GI cancer appears to be less immunogenic, as evidenced by the lack of infiltrating lymphocytes with advancing T stage as well as an immunosuppressive tumor micro-environment.
• Vascular Biogenics (VB)-111 is an anti-angiogenic agent comprising of a nonreplicating E1 deleted adenovirus type 5 which contains a modified murine preproendothelin (PPE) promoter and Fas-chimera transgene
• VB-111 has been tested and shows promise in glioblastoma, ovarian and thyroid tumors
• Nivolumab is a human monoclonal antibody directed against programmed cell death protein 1 (PD-1).
• The aim of this study is to study the effects of VB-111 in colorectal cancer (CRC) and to evaluate whether the antitumor immunity induced by VB-111 therapy can be enhanced by PD-1 inhibition.

Objectives:

• To determine the safety and tolerability of VB-111 in combination with nivolumab in patients with refractory, metastatic CRC
• To determine Best Overall Response (BOR) (partial response (PR) + complete response (CR)) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) of combined treatment of VB-111 and nivolumab in patients with refractory, metastatic CRC.

Eligibility:

• Histopathological confirmation of colorectal cancer metastatic to the liver
• Patients must have progressed on > 2 lines of standard of care chemotherapy for colorectal cancer or been intolerant of chemotherapy or refused prior chemotherapy.
• Patient's tumors must be documented to be microsatellite stable (MSS).
• Patients must have at least 1 focus of metastatic disease that is amenable to pre-and on-treatment biopsies and be willing to undergo this.
• All patients enrolled will be required to have measurable disease by RECIST v 1.1 criteria.

Design:

• The proposed study is a phase II study of VB-111 in combination with immune checkpoint inhibition (nivolumab) in patients with metastatic CRC
• Treatment will be delivered in cycles consisting of 2 weeks with VB-111 given every 6 weeks and nivolumab given every 2-week until progression or unacceptable toxicity.
• Disease status evaluation will be done every 8 (+/- 1) weeks after the start of study therapy.

Conditions

Metastatic Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Cancer With Hepatic Metastases; Colorectal Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1/Arm 1

Vascular Biogenics (VB)-111 and nivolumab

Group Type: EXPERIMENTAL

Vascular Biogenics (VB)-111

Intervention Type: BIOLOGICAL

1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks

Nivolumab

Intervention Type: DRUG

240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks

Interventions

Vascular Biogenics (VB)-111

1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks

Intervention Type: BIOLOGICAL

Nivolumab

240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks

Intervention Type: DRUG

Other Intervention Names

Opdivo

Eligibility Criteria

Inclusion Criteria

• Patients must have histopathological confirmation of colorectal cancer.
• Patients must have radiologically confirmed liver metastasis.
• Patients must:

• have progressed on > 2 lines of standard of care chemotherapy for colorectal cancer

OR

--been intolerant of standard of care chemotherapy for colorectal cancer

OR

• refused prior standard of care chemotherapy for colorectal cancer.

• Patients who have a known Kirsten rat sarcoma (KRAS) wild type tumor must have progressed, been intolerant of or refused anti-epidermal growth factor receptor (EGFR) based treatment.
• Patient's tumors must be documented to be microsatellite stable (MSS).
• Patients must have at least 1 focus of metastatic disease that is amenable to pre- and on-treatment biopsies and be willing to undergo this. Ideally, the biopsied lesion should not be one of the target measurable lesions, although this can be up to the discretion of the investigator's
• Patients must have measurable disease by RECIST v 1.1 criteria.
• Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of nivolumab in combination with Vascular Biogenics (VB)-111 in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Adequate hematological function defined by:
• white blood cell (WBC) count greater than or equal to 3x10(9)/L
• absolute neutrophil count (ANC) greater than or equal to 1.5x10(9)/L
• lymphocyte count greater than or equal to 0.5x10(9)/L
• platelet count greater than or equal to 100x10(9)/L
• Hemoglobin (Hgb) greater than or equal to 9 g/ dL (more than 48 hours post-completion of blood transfusion)

• Prothrombin time (PT) and Partial thromboplastin time (PTT) (seconds) < 1.2 x ULN. Patients who are anticoagulated do not need to meet criteria for PT and PTT
• International normalized ratio (INR) < 1.2 x ULN. Patients who are anticoagulated do not need to meet criteria for INR.
• Adequate hepatic function defined by:
• a total bilirubin level less than or equal to 1.5 x ULN,
• an Aspartate transaminase (AST) level less than or equal to 2.5xULN in the absence of hepatic metastasis; or less than or equal to 5 x ULN in the presence of hepatic metastases,
• an Alanine transferase (ALT) level less than or equal to 2.5xULN in the absence of hepatic metastasis; or less than or equal to 5 x ULN in the presence of hepatic metastases

-Adequate renal function defined by:

• Creatinine OR Measured or calculated creatinine clearance (CrCl) (estimated glomerular filtration rate (eGFR) may also be used in place of CrCl) (A Creatinine clearance (CrCl) or eGFR should be calculated per institutional standard.):

• < 1.5x institution upper limit of normal OR

greater than or equal to 50 mL/min/1.73 m(2) for participant with creatinine levels greater than or equal to 1.5 X institutional ULN

• The effects of nivolumab and VB-111 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation and up to 5 months (women) and 7 months (men) after the last dose of the nivolumab or 2 months after the last dose of VB-111 whichever is the longer time period. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
• Troponin level in normal range at the time of enrollment.
• Patient must be able to understand and willing to sign a written informed consent document.
• Weight > 35kg
• Patients must be enrolled in tissue collection protocol 11C0112.

Exclusion Criteria

• Patients who have had standard-of-care anti-cancer therapy or therapy with investigational agents (e.g., chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies or other investigation agents), large field radiotherapy, or major surgery within 4 weeks prior to enrollment.
• Patients who have had anti-vascular endothelial growth factor (VEGF) therapy within 4 weeks prior to enrollment.
• Patients currently on a corticosteroid dose greater than physiologic replacement dosing defined as 10 mg of cortisone per day or its equivalent.
• Patients with known brain metastases because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
• Patients with signs of liver failure, e.g., clinically significant ascites, encephalopathy, or variceal bleeding within 6 months prior to enrollment.
• Prior major liver resection: remnant liver <50% of the initial liver volume. Patients with a biliary stent can be included.
• Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), myasthenia gravis; systemic autoimmune disease such as Systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome. Such diseases should be excluded because of the risk of recurrence or exacerbation of disease.

Of note, patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.

• History of idiopathic pulmonary fibrosis (including bronchiolitis obliterans with organizing pneumonia) or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations (within timeframes identified in the bullets below) that would limit compliance with study requirements.
• History of severe or unstable cerebrovascular disease.
• Pulse oximetry < 92% on room air
• Myocardial infarction within 6 months prior to enrollment
• History of myocarditis
• Sustained hypotension (<90/50 mmHg) or uncontrolled hypertension (>160/100 mmHg)
• Stroke within 6 months prior to enrollment.
• Patients with proliferative and/or vascular retinopathy.
• Significant vascular disorders (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to enrollment.
• History of hemoptysis (> 1/2 teaspoon of bright red blood per episode) or active gastrointestinal (GI) bleeding within 6 months prior to enrollment.
• Evidence of a bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
• History of abdominal fistula or gastrointestinal perforation within 6 months prior to enrollment.
• Human immunodeficiency virus (HIV)-positive patients are excluded because HIV causes complicated immune deficiency and study treatment can possess more risks for these patients.
• Prior autologous or allogenic hematopoietic stem cell transplant.
• Subjects with ascites.
• Patients with unhealed surgical wounds for more than 30 days.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or VB-111.
• History of severe hypersensitivity reaction to any monoclonal antibody.
• Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years prior to enrollment.
• Pregnant women are excluded from this study because nivolumab and VB-111 potential for teratogenic or abortifacient effects are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with nivolumab and VB-111, breastfeeding should be discontinued if the mother is treated with nivolumab and/or and VB-111.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Tim Greten, M.D.

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Tim F Greten, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Cancer Institute (NCI)

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Countries

United States

References

Coffman-D'Annibale K, Myojin Y, Monge C, Xie C, Hrones DM, Wood BJ, Levy EB, Kleiner D, Figg WD, Steinberg SM, Redd B, Greten TF. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial. J Immunother Cancer. 2024 Jan 6;12(1):e008079. doi: 10.1136/jitc-2023-008079.

Reference Type: DERIVED

PMID: 38184304 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Related Links

https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2020-C-0022.html

NIH Clinical Center Detailed Web Page

Other Identifiers

20-C-0022

Identifier Type: -

Identifier Source: secondary_id

200022

Identifier Type: -

Identifier Source: org_study_id